Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

October 17, 2018 admin CEO Interview, Healthcare Comments Off on Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

tetra logo

 

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

Guy Chamberland

 

 

 

 

 

Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., shares update on Tetra’s Cannabinoid-based drug pipeline as opioid alternative.

Investor Presentation Deck
Tetra Investor Presentation




Related Articles

Healthcare

CytoDyn (OTC: CYDY) Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV

March 21, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV

FDA Previously Granted Rolling Review for BLA VANCOUVER, Washington, Mar 18, 2019 – CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential […]

Consumer

Medicine Man Technologies (OTC: MDCL) to Acquire an Additional Four Dispensaries from an Established Retailer – Largest Transaction in Company History

September 9, 2019 admin Consumer, Newsmakers Comments Off on Medicine Man Technologies (OTC: MDCL) to Acquire an Additional Four Dispensaries from an Established Retailer – Largest Transaction in Company History

– This group of four dispensaries is expected to have EBITDA margins of 35% in 2019 and will be among the most profitable retail locations in the Company’s portfolio, upon transaction closing- Company is now […]

Newsmakers

CytoDyn’s (OTC: CYDY) Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies

November 20, 2019 admin Newsmakers Comments Off on CytoDyn’s (OTC: CYDY) Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies

CytoDyn will file for expanded access IND for patients with pancreatic, prostate, lung, breast, liver and melanoma cancers VANCOUVER, Washington, Nov 19, 2019  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology […]